How have changes in approaches to diagnosis led to changes in the
  approaches to drug development?

How can diagnosis be best addressed in future drug development efforts?

What new strategies for collaboration (e.g., industry/academia/government)
   might speed the development of biomarkers and drug development?

How can new technological advances (e.g., methods of patient monitoring
   or data collection and analysis) be integrated in clinical trials?

How can we maximize the potential utility of public data sets?

What special issues are involved in the conduct of trials examining
   combined treatments?

How can studies be designed to examine individuals with illnesses
   co-occurring with mental disorders, including physical, substance use,
   and other mental illnesses?

How can interventions be tailored to different types of providers and different
   intervention settings?

How can newly discovered effective mental health interventions be
   disseminated and implemented?

What adaptive designs can be used in trials of combined psychosocial and
   biomedical interventions?

     Join the NCDEU listserv to get e-mail updates on meeting activities